The Ahead Study: 2nd Interim Analysis Results in 376 Patients with Haemophilia A

被引：0
|
作者：
Oldenburg, J. [1 ]
Tsakiris, D. A. [2 ]
Hermans, C. [3 ]
Liesner, R. [4 ]
Mazzucconi, M. G. [5 ]
Franch, L. Abad [6 ]
Steinitz-Trost, K. [7 ]
Gringeri, A. [8 ]
机构：
[1] Bonn Univ Clin, Inst Expt Hematol & Transfus Med, Bonn, Germany
[2] Univ Basel Hosp, Diagnost Hematol, CH-4031 Basel, Switzerland
[3] St Luc Univ Hop, Div Hematol, Brussels, Belgium
[4] Haemophilia Comprehens Care Ctr, London, England
[5] Univ Roma La Sapienza, Policlin Umberto I, Piazzale Aldo Moro 5, I-00185 Rome, Italy
[6] Baxalta GmbH, EMEA Med Affairs Haematol, Zurich, Switzerland
[7] EMEA Med Affairs Haematol, London, England
[8] Baxalta Innovat GmbH, Vienna, Austria
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P065
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [21] AHEAD study update: interim results from the first year of observation
    Oldenburg, J.
    Tsakiris, D.
    Hermans, C.
    Abraham, I.
    Loew-Baselli, A.
    Pina, P.
    Spotts, G.
    Reininger, A. J.
    HAEMOPHILIA, 2014, 20 : 51 - 51
  • [22] INTENSIVE-CARE FOR PATIENTS WITH REMOVABLE PROSTHESES - RESULTS AFTER THE 2ND STUDY YEAR
    KATAY, L
    KERSCHBAUM, T
    DEUTSCHE ZAHNARZTLICHE ZEITSCHRIFT, 1987, 42 (04): : 330 - 333
  • [23] Feasibility of a 2nd cycle of catumaxomab treatment in patients with malignant ascites: results of the SECIMAS study
    Oskay-Oezcelik, G.
    Vergote, I
    Santoro, A.
    Marme, F.
    Rosenberg, P.
    Sehouli, J.
    ONKOLOGIE, 2012, 35 : 62 - 62
  • [24] Southeast Asia: The Long Road Ahead, 2nd ed
    Fazio, Helen Asquine
    JOURNAL OF ASIAN ECONOMICS, 2006, 17 (04) : 758 - 759
  • [25] Editorial: The 2nd European Clinical Nanomedicine Conference is ahead
    Loffler, Beat
    EUROPEAN JOURNAL OF NANOMEDICINE, 2009, 2 (01) : 5 - 5
  • [26] Interim results from a prospective, non-interventional study on the use of rVIII-SingleChain in patients with haemophilia A
    Oldenburg, J.
    Juranek, S.
    Katsarou, O.
    El Fegoun, S. Benchikh
    Pabinger, I.
    HAEMOPHILIA, 2024, 30 : 50 - 51
  • [27] Results of a phase II trial of a fludarabine with concomitant application of alemtuzumab in a four-weekly schedule (FluCam) in patients with relapsed CLL.: 2nd Interim analysis
    Elter, T
    Borchmann, P
    Schulz, H
    Reiser, M
    Trelle, S
    Staib, P
    Schinköthe, T
    Engert, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 605S - 605S
  • [28] PROGNOSIS OF EPILEPSY - 2ND INTERIM-REPORT OF A MULTI-INSTITUTIONAL STUDY IN JAPAN
    OKUMA, T
    KUMASHIRO, H
    FOLIA PSYCHIATRICA ET NEUROLOGICA JAPONICA, 1978, 32 (03): : 421 - 431
  • [29] RESULTS OF THE 2ND NATIONAL WILMS TUMOR STUDY (NWTS-2)
    DANGIO, GJ
    BECKWITH, JB
    BRESLOW, N
    SINKS, L
    SUTOW, W
    WOLFF, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 309 - 309
  • [30] Clinical features and outcome of acquired haemophilia A Interim analysis of the Dusseldorf Study
    Gheisari, R.
    Bomke, B.
    Hoffmann, T.
    Scharf, R. E.
    HAMOSTASEOLOGIE, 2010, 30 (4A): : S39 - S39
12345